PharVision Advisers’s Enovix ENVX Stock Holding History

PharVision Advisers’s Portfolio ENVX Stock Details ENVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,707	Closed	-$149K	–	342
2024 Q4	$149K	Buy	+15,707	New	+$138K	0.13%	347

Other funds holding ENVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECP

Electron Capital Partners New York $2.55B AUM 87.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PharVision Advisers's ENVX Position: Q1 2025 in Review

PharVision Advisers sold out of Enovix (ENVX) in Q1 2025, closing a stake of 15,707 shares — an estimated $149K sold.

PharVision Advisers first reported a position in ENVX in Q4 2024 and held it in 1 quarter. The position peaked at $149K in Q4 2024. 315 funds tracked by Wall St. Rank hold ENVX as of Q1 2025.

PharVision Advisers reported no remaining Enovix position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 15,707 Enovix shares in Q1 2025, an estimated $149K.
PharVision Advisers first reported a position in Enovix in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Enovix position peaked at $149K in Q4 2024.
315 funds tracked by Wall St. Rank held Enovix as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.